Annovis completes enrollment in Phase 3 Alzheimer's trial of buntanetap
The company reported 850 patients enrolled, above its original target, with topline data still expected in early 2027.
SEC filing
Latest
2 stories
Sign inSign in2 stories
The company reported 850 patients enrolled, above its original target, with topline data still expected in early 2027.
SEC filing